Skip to content

Postoperative Pain Therapy With Hydromorphone TCI-PCA vs. Morphine PCA

Phase 4 Study of Postoperative Pain Therapy With Hydromorphone Using Patient-Controlled Target-Controlled Infusion (TCI-PCA) vs. Patient-Controlled Analgesia (PCA) With Morphine After Elective Cardiac Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02483221
Enrollment
50
Registered
2015-06-26
Start date
2015-04-30
Completion date
2016-12-01
Last updated
2017-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Postoperative Pain

Brief summary

Treatment of postoperative pain with hydromorphone (a strong analgesic) using patient-controlled analgesia with target-controlled infusion compared to conventional patient-controlled analgesia with morphine after elective cardiac surgery

Interventions

DRUGHydromorphone

Hydromorphone is given intravenously by TCI-PCA. The TCI-PCA system steer the hydromorphone infusion pump to achieve plasma and effect-site concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma and effect-site concentration range, lockout times and infusion speed.

DRUGMorphine

Morphine is given intravenously by PCA. The PCA pump administers a predefined bolus dose on patient request considering the predefined lockout time and infusion speed.

Sponsors

German Federal Ministry of Education and Research
CollaboratorOTHER_GOV
University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Written informed consent * Scheduled for elective cardiac surgery involving thoracotomy and subsequent ICU stay

Exclusion criteria

* Administration of other analgesics or sedatives, if not administered in stable dosages for at least 14 days or if not used for premedication and surgery * Administration of hydromorphone or morphine in the period between screening and surgery * Severe hepatic or renal impairment in medical history * BMI\>= 35 ASA\>= 4

Design outcomes

Primary

MeasureTime frameDescription
Numerical Rating Scoreup to 17 hours after extubationComparison of pain analgetic efficacy between hydromorphone TCI-PCA and conventional morphine PCA during the early postoperative stage

Secondary

MeasureTime frameDescription
Modified Observer's Assessment of Alertness/Sedation Scaleup to 17 hours after extubationComparison of opioid induced sedation level between hydromorphone TCI-PCA and conventional morphine PCA during the early postoperative stage
Postoperative Nausea and Vomitingday of surgeryComparison of opioid associated nausea and vomiting between hydromorphone TCI-PCA and conventional morphine PCA during the early postoperative stage
Respiratory Frequencyup to 17 hours after extubationComparison of opioid induced respiratory depression between hydromorphone TCI-PCA and conventional morphine PCA during the early postoperative stage

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026